Classical Hodgkin lymphoma (cHL) is a malignancy of B-cell origin in which the neoplastic cells, known as ''Reed-Sternberg'' (RS) cells, are characteristically binucleated. Here we describe a family where multiple individuals developing cHL have inherited a reciprocal translocation between chromosomes 2 and 3. The translocation disrupts KLHDC8B, an uncharacterized gene from a region (3p21.31) previously implicated in lymphoma and related malignancies, resulting in its loss of expression. We tested KLHDC8B as a candidate gene for cHL and found that a 5-UTR polymorphism responsible for decreasing its translational expression is associated with cHL in probands from other families with cHL and segregates with disease in those pedigrees. In one of three informative sporadic cases of cHL, we detected loss of heterozygosity (LOH) for KLHDC8B in RS cells, but not reactive T lymphocytes, purified from a malignant lymph node. KLHDC8B encodes a protein predicted to contain seven kelch repeat domains. KLHDC8B is expressed during mitosis, where it localizes to the midbody structure connecting cells about to separate during cytokinesis, and it is degraded after cell division. Depletion of KLHDC8B through RNA interference leads to an increase in binucleated cells, implicating its reduced expression in the formation of cHL's signature RS cell.
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cancer ͉ cytokinesis C lassical Hodgkin lymphoma (cHL) (1) is a lymph node cancer of germinal center B-cell origin. cHL tumors consist of a minority of malignant ''Reed-Sternberg'' (RS) cells mixed with reactive lymphocytes and other benign inflammatory cells. A defining feature of RS cells is the presence of two nuclei. cHL, along with nasopharyngeal carcinoma and a few other malignancies, is associated with Epstein-Barr virus (EBV) exposure (2) , but genetic factors also contribute to risk.
In fact, the familial risk for cHL is very high. The risk in first degree relatives of cases is elevated 3-to 4-fold compared with the general population; the risk is greater still when onset of cHL in the proband is under age 40 (3) . A recent genome-wide scan detected multiple loci possibly linked to familial cHL (4) , indicating that genetic heterogeneity may pose a challenge for the identification of cHL susceptibility genes through a linkagebased strategy. Chance ascertainment of rare families cosegregating chromosomal abnormalities remains an established paradigm for disease gene identification, however, and was the approach that initially led to discovery of tumor suppressor genes responsible for retinoblastoma (5) and familial adenomatous polyposis (6) , among other types of cancer.
Here we report a family where several individuals carrying a constitutional translocation involving chromosomes 2 and 3 have developed cHL. Intriguingly, the breakpoint on chromosome 3 is situated in a region (3p21.31) where frequent somatic cytogenetic rearrangements have been observed for both cHL and nonHodgkin lymphoma (7) . Additionally, genetic linkage analysis (8) , chromosome transfer experiments (9) , and loss of heterozygosity (LOH) studies (10) have also implicated 3p21.31 in nasopharyngeal carcinoma, which shares an association with EBV. Moreover, 3p21.31 LOH is common in breast cancer (11) , and breast cancer occurs more often among first degree relatives of cHL patients than in the general population (3). We therefore proceeded to molecularly define the translocation to determine if it disrupts a gene that may contribute to development of cHL and other forms of cancer.
Results
Description of the Family. In this pedigree (Fig. 1A) , cHL has occurred in conjunction with a constitutional chromosomal abnormality. The proband developed the nodular sclerosis type of cHL at age 39. Two siblings also developed nodular sclerosis cHL as adults. Their mother died shortly after presenting with a mediastinal tumor (which is compatible with cHL, based on its location), for which she declined workup. A maternal first cousin succumbed to a brainstem tumor (which was probably not cHL, because it is only rarely found here). Individuals with cancer for whom genetic material is available or for whom karyotype can be inferred inherited a t(2,3) (q11.2;p21.31) translocation (Fig. 1B) .
Mapping the 3p21.31 Translocation Breakpoint within KLHDC8B. We initially used fluorescence in situ hybridization (FISH) to map bacterial artificial chromosomes (BACs) spanning the breakpoints, as revealed by ''split'' signals appearing on both normal and derivative chromosomes. Metaphase FISH of lymphoblastoid cells derived from a t(2,3)-carrying family member localized breakpoints to a segment on chromosome 3 containing two genes and to a region on chromosome 2 lacking apparent genes ( Fig. 2A and B) . We next hybridized Southern blots containing restriction digested genomic DNA with probes from each of the This article is a PNAS Direct Submission. 1 Present address: Perlegen Sciences, Mountain View, CA 94043. 2 To whom correspondence should be addressed. E-mail: horwitz@u.washington.edu.
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two genes from 3p21.31. One of them (KLHDC8B) yielded extra bands absent in an unaffected family member lacking the translocation (Fig. 2C) , thus narrowing the interval to a region short enough to amplify by long-range PCR (Fig. 2D) . We then progressively refined the interval by PCR (Fig. 2E ) and used DNA sequencing to define precise breakpoints (Fig. 2F ). The chromosome 3 breakpoint resides in the first intron of KLHDC8B. The chromosome 2 breakpoint is not located near known or hypothetical genes. Chromosomes 2 and 3 exhibit four base pairs of microhomology at the Der3 junction, and there is a four base pair nonhomologous insertion at the Der2 junction. We additionally excluded possible cryptic rearrangements by array-based comparative genomic hybridization. In sum, the translocation disrupts KLHDC8B and replaces sequences upstream of and including its first exon and part of its first intron with an intergenic region from chromosome 2, thus deleting its 5Ј-UTR and probable promoter sequences. Accordingly, quantitative real-time (QR) reverse transcription (RT)-PCR in lymphoblastoid cells shows that a translocation-carrying individual expresses only about half as much KLHDC8B as a family member without the translocation (Fig. 2G) . Western blot confirms correspondingly reduced expression of protein, see below (Fig.  3C ).
Association and Linkage with a KLHDC8B 5-UTR Variant in Other cHL
Pedigrees. We investigated whether mutations in this gene might occur in other cases of familial cHL. We screened probands from 52 families that each had two or more individuals affected with cHL. Sequencing of exons and adjacent regions, as well as copy number analysis, did not reveal any variants likely to alter protein coding or splicing. However, we did find a previously unreported single nucleotide polymorphism (SNP) in the 5Ј-UTR at ϩ28 (with respect to transcription initiation). Heterozygous C3T substitution was present in affected probands from 3 of 52 (5.8%) cHL families, compared with just 4 of 307 controls (1.3%), yielding an odds ratio of 4.64 (95% confidence interval 1.01-21.4). Moreover, the variant segregates with cHL in each of these three pedigrees (Fig. 3A) ; of 13 individuals heterozygous for the C/T variant, seven have had cHL, whereas, of five individuals who are homozygous for the common allele (C/C), none have had any malignancy (nonparametric LOD ϭ 1.20, P Ͻ 0.01). The KLHDC8B variant therefore appears to be both associated and linked with cHL. Additionally, one C/T heterozygote has had lung cancer and two C/T heterozygotes have had both lung cancer and cHL. Of relevance, deletions of chromosome 3p21.3 are among the commonest and earliest known genetic alterations occurring in lung cancer (12) . Translational Effect of the 5-UTR Variant. The variant substitutes a highly conserved nucleotide residing in one of multiple poly(C) repeats in the 5Ј-UTR (Fig. 3B) . To determine if this polymorphism influences expression, we performed Western blots on protein extracts from lymphoblastoid cells. Compared with those homozygous for the more common C-containing allele, in two different sets of people, heterozygosity for the ϩ28C3T variant produces lower levels of KLHDC8B, although its effects are less pronounced than the translocation (Fig. 3C and Fig. S1 ). To determine how the variant influences expression, we first bacterially subcloned and sequenced cDNA from heterozygous lymphoblastoid cells, but found that each allele was represented in approximately equal proportions, excluding a transcriptional effect. To determine if the variant alters translation, we then evaluated expression in transfected HeLa cells using a recombinant reporter. We fused a portion of KLHDC8B, beginning from its 5Ј-UTR and extending six bases beyond the ATG initiation codon, in-frame to a luciferase gene lacking an initiation codon. The single base substitution at ϩ28 reduces luciferase fusion gene expression by approximately half (Fig. 3D) , demonstrating that the variant affects translation of the mRNA.
LOH for KLHDC8B in RS Cells. We then determined if KLHDC8B acquires somatic mutations in sporadic cases of cHL. Most lymphocytes contained within a Hodgkin lymphoma are reactive; malignant RS cells actually comprise just a minute fraction of the tumor (1). We therefore used fluorescence-activated cell sorting (FACS) to separate RS cells from reactive T and B cells in tumors obtained from six cHL patients. We did not detect any DNA sequence alterations in genomic DNA from transcribed regions of the gene in RS cells. We next assayed for possible LOH as an indication of somatic deletion or gene conversion events. RS cells isolated from the tumor of one patient demonstrated LOH for five SNPs from within and flanking KLHDC8B (Fig. 4 and Dataset S1). RS cells from another two patients each demonstrated heterozygosity for different informative SNPs from within KLHDC8B (Dataset S1), indicating that LOH was unlikely (although a small region of LOH cannot be excluded). For the remaining three patients, no informative SNPs could be identified (Dataset S1). Thus, out of three informative sporadic Localization of KLHDC8B at the Midbody. KLHDC8B is a widely expressed (per publicly available databases) yet previously uncharacterized gene predicted to encode a protein consisting of nothing but seven kelch domains (13) , which fold into ␤-propeller structures capable of participating in protein-protein interactions (13) . Kelch repeat-containing proteins comprise a large family with diverse activities (13) . To characterize its function, we generated antibodies to KLHDC8B and evaluated its subcellular distribution by immunofluorescent staining of HeLa cells (where our preliminary studies showed it is also transcribed). KLHDC8B accumulates most strongly in mitotic cells and concentrates in the midbody of the cytoplasmic bridge linking daughter cells as they are about to separate during cytokinesis ( Fig. 5A and Fig. S2 ). To determine if KLHDC8B expression is cell cycle-regulated, we synchronized HeLa cells at G1 by release from a double-thymidine block and collected fractions at successive time points. Flow cytometry, western blot, and QR RT-PCR demonstrate that KLHDC8B is transcribed predominantly during S phase, translated exclusively during mitosis and cytokinesis (when the 4N population is transitioning to 2N), and is rapidly degraded after cell division (Fig. 5B) .
Based on its timing and location of expression, KLHDC8B appears to be involved in cytokinesis.
Binucleation After Depletion of KLHDC8B. In general, when cytokinesis fails, the cleavage furrow regresses, resulting in binucleated cells (14) . To determine if loss of KLHDC8B can disrupt cytokinesis and cause binucleation, we used RNA interference to deplete its expression in HeLa cells. Flow cytometry demonstrates that reducing KLHDC8B expression to about half normal level [as measured by QR RT-PCR (Fig. 6A) , and western blot (Fig. 6B)] , yields an increased proportion of cells with 4N DNA content (Fig. 6C) . We then microscopically examined shRNAtreated cells and found that, whereas the overall proportion of cells engaged in mitosis is unchanged, there is an increased frequency of binucleated cells (Fig. 6 D and E) . As a control for off-target effects of RNAi, we tested two additional shRNAs and found that each elevated binucleated cell production in relation to how well it functioned in silencing KLHDC8B (Fig. S3 ). Finally, we tested whether we could complement RNAi's effect on binucleation by expressing an RNAi-resistant form of KLHDC8B. We cotransfected siRNA targeting either the 5Ј-or 3Ј-UTR of the endogenous gene along with cDNA correspondingly lacking either only the 5Ј-or 3Ј-UTR (Fig. S4) . Compared with a control expressing ␤-galactosidase, the cDNA missing only the 3Ј-UTR indeed reversed binucleation resulting from the siRNA targeting the 3Ј-UTR, whereas the cDNA lacking the 5Ј-UTR (which still contains the 3Ј-UTR and should remain vulnerable to siRNA targeting the 3Ј-UTR) did not. For the siRNA targeting the 5Ј-UTR of KLHDC8B, the construct lacking only the 3Ј-UTR did not complement binucleation, as expected; however, cDNA deleted of its 5Ј-UTR could not fully complement the binucleation defect. The most likely explanation for the latter is that the 5Ј-UTR of KLHDC8B is necessary for its appropriate function in cytokinesis-an interpretation consistent with the observed effects of genetic variants in the 5Ј-UTR in familial cHL. Reduced expression of KLHDC8B leads to formation of binucleated cells, thus recapitulating a hallmark of cHL.
Discussion
We discovered a constitutional translocation disrupting transcription of KLHDC8B in a family with multiple cases of cHL. In the general population, 0.29-0.56% carries a balanced translocation, but, because relatively little of the genome encodes genes, only very few translocations actually interrupt genes (15) . Moreover, among lymphocytes, KLHDC8B is expressed most strongly in germinal center B cells (16) , which are the malignant cell of origin for cHL. The translocation seems unlikely to be only coincidentally related to cHL in this family. Additionally, we found that a 5Ј-UTR variant that reduces KLHDC8B translation is associated with familial cHL and linked to disease in three other families. The 5Ј-UTR variant is located within a poly(C) repeat cluster. RNA-binding, KH domaincontaining proteins recognize poly(C) repeats (17) and participate in cap-independent translation (18) . Significantly, KLHDC8B is translated only during mitosis and cytokinesis, when cap-dependent translation is extinguished and only capindependent translation is available (19) . The 5Ј-UTR variant may therefore disrupt KLHDC8B's mitotic expression. More studies are needed, however, to determine if this variant acts as a causative mutation or whether it might modify risk for developing cHL or other cancers in concert with other genetic and environmental factors.
RS cells from one of three informative sporadic cases of cHL demonstrate LOH for KLHDC8B. Although intriguing, the extent of LOH remains large, and we were unable to obtain sufficient material to evaluate for additional genetic alterations. The contribution of somatic mutations of KLHDC8B to sporadic cHL requires further study.
The kelch domain was initially discovered as a repeated element in an oligomeric actin-organizing Drosophila protein serving as a component of ''ring canals,'' which are structures that interconnect germ cells remaining physiologically coupled after incomplete cytokinesis (20) . Other kelch proteins also participate in cytokinesis. Coiled-coil kelch proteins Kel1p and Kel2p (21) and Tea1p (22) function to correctly position the bud neck and cell division plane, respectively, in budding and fission yeast. The mammalian BTB/POZ-kelch protein, Keap1, which has a more well-established role in coordinating response to oxidative stress via recruitment of cullin E3 ubiquitin ligase (Cul3) to the transcription factor Nrf2 (23), is one of just a few proteins that, like KLHDC8B, are known to locate to the midbody's central matrix (24) . Recently, two more BTB/POZkelch proteins, KLHL9 and KLHL13, were discovered in the midbody, where they associate with the Aurora kinase spindle checkpoint regulator and also direct its ubiquitination by Cul3 (25) . Silencing of Keap1 (24), KLHL9 (25) , and KLHL13 (25) similarly increases binucleated cell formation. Another BTB/ POZ-kelch protein, Nd1, participates in cytoskeletal organization, and overexpression retards cytokinesis (26) .
Most provocatively, the binucleated RS cell of cHL forms as a consequence of defective cytokinesis (27) , rather than through cell fusion (28) , and we demonstrate that KLHDC8B participates in cytokinesis, where its reduced expression leads to formation of binucleated cells. Overall, our observations are consistent with a hypothesis, originally formulated nearly a century ago by Boveri, that defective cytokinesis promotes tumorigenesis through the formation of genetically unstable tetraploid cells (29) . An implication is that other midbody proteins may prove to represent a general class of tumor suppressors. Supportive observations include recent demonstrations that somatic mutations of KEAP1 are frequent in lung cancer (30) and that BRCA1 (31), BRCA2 (32) , and BRCA1-associated protein BARD1 (33) , in addition to other important contributions to cancer, also each locate to the midbody during cytokinesis.
Materials and Methods
Cases and Controls. Cases were recruited under Human Subjects Committeeapproved protocols. Control individual genomic DNA and lymphoblastoid cell lines were obtained (via Sigma-Aldrich) from the European Collection of Animal Cell Cultures (ECACC).
FISH. BAC clones were provided by the Children's Hospital of Oakland Research Institute BACPAC Resource Center. BACS were labeled with a nick translation kit (Roche) using fluorescein-12-dUTP or tetramethyl-rhodamine-6-dUTP. Hybridization was performed as described (34) .
Purification of RS Cells. RS and nonmalignant reactive lymphocytes were purified from lymph node suspensions via flow cytometric cell sorting using a mixture of antibodies (35) .
Mutational Analysis. We performed DNA sequencing with the ABI BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems). We screened all six KLHDC8B exons and intron-exon junctions. To evaluate copy number variation, we additionally performed exonic multiplex ligation-dependent probe amplification using SALA MLPA reagent kits (MRC-Holland). For LOH analysis, we selected known SNPs from dbSNP (http://www.ncbi.nlm.nih.gov/projects/ SNP) and sequenced KLHDC8B introns in sporadic cHL cases to search for previously unreported SNPs.
Statistics.
The association between the 5Ј-UTR variant and cHL was calculating using the odds ratio (36) . The nonparametric LOD score for segregation of the 5Ј-UTR variant within families was calculated using the Kong and Cox exponential model (37) , with observed allele frequencies for cases and controls, using the MERLIN software package (38) . P values for luciferase and shRNA assays derive from two-tailed, two-sample T-tests assuming equal variances.
Quantitative RT-PCR. Total RNA was prepared from lymphoblastoid or HeLa (obtained from ATCC) cells using the Absolutely RNA Miniprep kit (Stratagene) and used to produce randomly primed cDNAs with the Omniscript RT kit (Qiagen). QR RT-PCR was performed using an ABI 7300 real-time PCR system (Applied Biosystems). KLHDC8B TaqMan gene expression assays (HS00293902 m1) were obtained from Applied Biosystems and normalized to ACTB, encoding ␤-actin.
Luciferase Assays. We fused the KLHDC8B 5Ј-UTR extending downstream to the third amino acid residue of its protein coding sequence in-frame to the second amino acid residue of firefly luciferase (deleting the endogenous translation initiation codon in luciferase) in the pPK-CMV-CLuc Stable Fusion Protein Reporter Vector (PromoKine) and introduced the ϩ28C3 T variant by site-directed mutagenesis. Each of the wild-type and variant firefly luciferase fusion construct plasmids (3.75 g) was transfected with Lipofectamine (Invitrogen) along with 0.25 g pRL-TK Renilla luciferase as internal control in ϳ80% confluent HeLa cells on 10-cm plates and assayed 24 h later using the Promega Dual-Luciferase Reporter Assay System. Antibodies, Immunofluorescence, and Western Blotting. Chicken polyclonal IgY antibodies were raised (by Aves Labs) against KLHDC8B peptide 138DTAPQAQVRVYEPRRDC154. (Negative controls included preimmune and antigen-depleted sera.) Immunofluorescent staining of HeLa cells, fixed in 4% paraformaldehyde and permeabilized with 0.1% Triton X-100, used a 1:10,000 dilution of ␣-KLHDC8B and 1:500 dilution of ␣-tubulin (ab7291; Abcam) primary antibodies followed with a 1:500 dilution of Alexa Fluor 488-labeled goat anti-chicken and 1:500 Alexa 555-labeled goat anti-mouse secondary antibodies (Invitrogen), blocked with 0.5% BSA and 4Ј,6-diamino-2-phenylindole (DAPI) nuclear counterstaining. Images were obtained with a Zeiss 510 laser-scanning confocal microscope with 63ϫ Plan-Apochromat
